Investors

News / Events

Press Releases

April 16, 2019
Cortexyme Announces Phase 2/3 Clinical Trial Based On Transformational Understanding Of Alzheimer’s Disease
April 16, 2019
Cortexyme Announces Phase 2/3 Clinical Trial Based On Transformational Understanding Of Alzheimer’s Disease
April 16, 2019
Cortexyme Announces Phase 2/3 Clinical Trial Based On Transformational Understanding Of Alzheimer’s Disease
April 16, 2019
Cortexyme Announces Phase 2/3 Clinical Trial Based On Transformational Understanding Of Alzheimer’s Disease

Events

March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019

Presentations

March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019

Publications

January 25, 2019
Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors
October 24, 2018
A Randomized, Placebo-Controlled, Repeat Dose Phase 1 Study of COR388 in Older Healthy Volunteers and Patients With Alzheimer’s Disease